JPWO2021132472A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021132472A5 JPWO2021132472A5 JP2021567619A JP2021567619A JPWO2021132472A5 JP WO2021132472 A5 JPWO2021132472 A5 JP WO2021132472A5 JP 2021567619 A JP2021567619 A JP 2021567619A JP 2021567619 A JP2021567619 A JP 2021567619A JP WO2021132472 A5 JPWO2021132472 A5 JP WO2021132472A5
- Authority
- JP
- Japan
- Prior art keywords
- mpges
- trifluoromethyl
- inhibitor
- benzimidazole
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710096361 Prostaglandin E synthase Proteins 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000000450 Pelvic Pain Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 208000013507 chronic prostatitis Diseases 0.000 claims 3
- 230000003449 preventive effect Effects 0.000 claims 3
- 201000007094 prostatitis Diseases 0.000 claims 3
- YNMKDEMTKFSAIN-UHFFFAOYSA-N n-(3-chloro-2-methylphenyl)-6-[[2-(trifluoromethyl)benzoyl]amino]-2-[1-(trifluoromethyl)cyclopropyl]-1h-benzimidazole-4-carboxamide Chemical compound CC1=C(Cl)C=CC=C1NC(=O)C1=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=CC2=C1N=C(C1(CC1)C(F)(F)F)N2 YNMKDEMTKFSAIN-UHFFFAOYSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- ZPONWJXTHMDOSV-UHFFFAOYSA-N n-(3-chloro-2-methylphenyl)-2-(methoxymethyl)-6-[[2-(trifluoromethyl)benzoyl]amino]-1h-benzimidazole-4-carboxamide Chemical compound C1=C2NC(COC)=NC2=C(C(=O)NC=2C(=C(Cl)C=CC=2)C)C=C1NC(=O)C1=CC=CC=C1C(F)(F)F ZPONWJXTHMDOSV-UHFFFAOYSA-N 0.000 claims 1
- SVHXOMRTGZARGF-UHFFFAOYSA-N n-(3-chloro-2-methylphenyl)-2-(methoxymethyl)-6-[[2-(trifluoromethyl)benzoyl]amino]-1h-benzimidazole-4-carboxamide;4-methylbenzenesulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1.C1=C2NC(COC)=NC2=C(C(=O)NC=2C(=C(Cl)C=CC=2)C)C=C1NC(=O)C1=CC=CC=C1C(F)(F)F SVHXOMRTGZARGF-UHFFFAOYSA-N 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
Claims (3)
- ｍＰＧＥＳ－１阻害剤を有効成分として含有する、慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤であって、
前記ｍＰＧＥＳ－１阻害剤が、
（１０）Ｎ－（３－クロロ－２－メチルフェニル）－２－（メトキシメチル）－６－（｛［２－（トリフルオロメチル）フェニル］カルボニル｝アミノ）－１Ｈ－ベンズイミダゾール－４－カルボキサミド、及び
（８８）Ｎ－（３－クロロ－２－メチルフェニル）－２－［１－（トリフルオロメチル）シクロプロピル］－６－（｛［２－（トリフルオロメチル）フェニル］カルボニル｝アミノ）－１Ｈ－ベンズイミダゾール－４－カルボキサミド
からなる群より選択される化合物若しくはその互変異性体又はその医薬上許容される塩である、予防及び／又は治療剤。 - ｍＰＧＥＳ－１阻害剤を有効成分として含有する、慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤であって、前記ｍＰＧＥＳ－１阻害剤が、Ｎ－（３－クロロ－２－メチルフェニル）－２－（メトキシメチル）－６－（｛［２－（トリフルオロメチル）フェニル］カルボニル｝アミノ）－１Ｈ－ベンズイミダゾール－４－カルボキサミド４－メチルベンゼンスルホン酸塩である、予防及び／又は治療剤。
- ｍＰＧＥＳ－１阻害剤を有効成分として含有する、慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤であって、前記ｍＰＧＥＳ－１阻害剤が、Ｎ－（３－クロロ－２－メチルフェニル）－２－［１－（トリフルオロメチル）シクロプロピル］－６－（｛［２－（トリフルオロメチル）フェニル］カルボニル｝アミノ）－１Ｈ－ベンズイミダゾール－４－カルボキサミドである、予防及び／又は治療剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019233865 | 2019-12-25 | ||
| JP2019233865 | 2019-12-25 | ||
| PCT/JP2020/048479 WO2021132472A1 (ja) | 2019-12-25 | 2020-12-24 | 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021132472A1 JPWO2021132472A1 (ja) | 2021-07-01 |
| JPWO2021132472A5 true JPWO2021132472A5 (ja) | 2024-04-30 |
| JP7499789B2 JP7499789B2 (ja) | 2024-06-14 |
Family
ID=76575232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021567619A Active JP7499789B2 (ja) | 2019-12-25 | 2020-12-24 | 慢性前立腺炎／慢性骨盤痛症候群の予防及び／又は治療剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230094705A1 (ja) |
| EP (1) | EP4082573A4 (ja) |
| JP (1) | JP7499789B2 (ja) |
| KR (1) | KR20220120646A (ja) |
| CN (1) | CN114867495A (ja) |
| AU (1) | AU2020413313A1 (ja) |
| BR (1) | BR112022012485A2 (ja) |
| CA (1) | CA3165891A1 (ja) |
| CO (1) | CO2022010343A2 (ja) |
| EC (1) | ECSP22058286A (ja) |
| IL (1) | IL294191A (ja) |
| MX (1) | MX2022007936A (ja) |
| PE (1) | PE20230164A1 (ja) |
| WO (1) | WO2021132472A1 (ja) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| WO2011048004A1 (en) * | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| KR101778354B1 (ko) | 2011-08-18 | 2017-09-13 | 니뽄 신야쿠 가부시키가이샤 | 헤테로환 유도체 및 의약 |
| KR20140095073A (ko) | 2011-11-04 | 2014-07-31 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 치료 방법 |
| US10710967B2 (en) * | 2015-10-29 | 2020-07-14 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
-
2020
- 2020-12-24 BR BR112022012485A patent/BR112022012485A2/pt unknown
- 2020-12-24 CN CN202080090316.8A patent/CN114867495A/zh active Pending
- 2020-12-24 US US17/788,516 patent/US20230094705A1/en active Pending
- 2020-12-24 IL IL294191A patent/IL294191A/en unknown
- 2020-12-24 CA CA3165891A patent/CA3165891A1/en active Pending
- 2020-12-24 KR KR1020227025732A patent/KR20220120646A/ko unknown
- 2020-12-24 JP JP2021567619A patent/JP7499789B2/ja active Active
- 2020-12-24 AU AU2020413313A patent/AU2020413313A1/en active Pending
- 2020-12-24 WO PCT/JP2020/048479 patent/WO2021132472A1/ja active Application Filing
- 2020-12-24 MX MX2022007936A patent/MX2022007936A/es unknown
- 2020-12-24 PE PE2022001326A patent/PE20230164A1/es unknown
- 2020-12-24 EP EP20905872.6A patent/EP4082573A4/en active Pending
-
2022
- 2022-07-22 CO CONC2022/0010343A patent/CO2022010343A2/es unknown
- 2022-07-25 EC ECSENADI202258286A patent/ECSP22058286A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501786A1 (en) | Hiv inhibitor compound | |
| MD3573983T2 (ro) | N-[4-fluoro-5-[[(2S,4S)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamidă în calitate de inhibitor OGA | |
| JP2020506946A5 (ja) | ||
| EP1632477A4 (en) | BENZAMID DERIVATIVE OR SALT THEREOF | |
| EA201170250A1 (ru) | Терапевтическое средство от мигрени | |
| JP2002053555A5 (ja) | ||
| RU2016117941A (ru) | Фениколовые противобактериальные средства | |
| NO20054452D0 (no) | Fremgangsmate for fremstilling av 5-[(R)-2-(5,6-dietyl-indan-2-ylamino)-1-hydroksyetyl]-8-hydroksy-(1H)-kinolin-2-on-salt som er nyttig som adrenoreseptoragonist | |
| NZ591427A (en) | P38 map kinase inhibitors | |
| CY1111932T1 (el) | Συνδυασμοι αγωνιστικης βητα-2-αδρενεργικης βενζοθειαζολονης | |
| DK1585743T3 (da) | 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme | |
| MX2021010133A (es) | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifl uorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carbox amida monohidratada. | |
| AR080472A1 (es) | Terapias de inhibidor de autofagia basado en tioxantona para tratar el cancer | |
| RS53131B (en) | N - ((1R, 2S, 5R) -5- (TERC-BUTYLAMINO) -2 - (S) -3- (7-TERC-BUTYLPYRAZOLO] [1,5-A] [1,3,5] TRIAZIN- 4-YLAMINO) -2-OXOPYROLIDIN-1-YL) CYCLICHEXYL) ACETAMIDE, DUAL MODULATOR OF HEMOKIN RECEPTOR ACTIVITY, CRYSTAL FORMS AND PROCEDURES | |
| MD3866767T2 (ro) | Compoziție farmaceutică pentru administrare orală care conţine derivat de aminopirimidină sau sarea acestuia | |
| JOP20210338A1 (ar) | نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد | |
| CO2021005141A2 (es) | Formas cristalinas sólidas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropano-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-trihidroxi-6-(metiltio)tetrahidro-2h-pirano-2-il)bencil)fenil)butanamida y métodos para su síntesis | |
| JPWO2021132472A5 (ja) | ||
| JP2006513222A5 (ja) | ||
| RS52260B (en) | N- (2-hydroxyethyl) -N-methyl-4- (quinoline-8-yl (1- (thiazol-4-ylmethyl) piperidin-4-ylidene) methyl) benzamide, a process for its production as well as its use for treatment PAIN, TENSION AND DEPRESSION | |
| JP2007516211A5 (ja) | ||
| RU2018122012A (ru) | БИС-пиридазиновые соединения и их применение в лечении рака | |
| JP2018520104A5 (ja) | ||
| DE602005007604D1 (de) | Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine | |
| NO20042871L (no) | Sitronsyre-salt av en terapeutisk forbindelse og farmasoytiske blandinger derav |